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DISINTEGRATION OF TABLETS AND CAPSULES MEASURED BY 
ISOTHERMAL THERMAL MECHANICAL ANALYSIS 
MACROPHOTGRAPHY AND U.V ANALYSIS 
 
VISWESWARARAO BADIPATLA  
ABSTRACT 
The current United States Pharmacopoeia (USP) test for tablet and encapsulated drug 
disintegration does not specify the initial disintegration time and provides limited 
information on the disintegration process itself. An isothermal Thermal Mechanical 
Analysis (IsoTMA) method is presented to measure the rate and initial time of drug 
disintegration, that is, the mechanical collapse of the gelatin capsule or the solid tablet. 
This method monitors changes in the dimensions of the formulated drugs during their 
disintegration in a liquid. Dimensional changes can be followed as a function of time, 
temperature, applied stress and pH. Some of the drugs studied were Olanzapine®, 
Ritalin® Amoxicillin® and .Graphical representations of their dimensional changes over 
time were compared for tablets and capsules from 25ºC to 37°C and pH 3 to 7. An 
increase in temperature decreases the overall disintegration time and increases the rate of 
disintegration (mm/min). For Abilify®, pH had an appreciable effect on the rate of 
disintegration.  
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OBJECTIVES 
 Develop a New Iso TMA Tablet And Capsule Disintegration Protocol 
 Determine Standard Derivation and % Relative error of IsoTMA of 
Tablets and Capsules  
 Determine the effect of Temperature and PH on drug disintegration rate in 
um/min or mm/min 
 Use Iso TMA Results to Predict drug target organ(oral, stomach,intestine) 
 Verify the Iso TMA results with macrophotography and UV 
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PROTOCOL 
Drug Disintegration OF TABLETS AND CAPSULES BY ISO TMA  
OVERVIEW: 
This document is a over view of drug test procedures in a outlined form so as to include 
all pertinent steps in a data collection, analysis and interpretation. 
SCOPE: 
The innovation of using polymer analysis tool, thermal mechanical analysis, to evaluate 
drug disintegration has led to a higher level of understanding how the drug is solublized 
and deliverd. This protocol is to guide pharmaceutical scientist to acquire relevant data to 
enhance their knowledge iin an organized manner. 
TERMINOLOGY: 
1.Define all significant terms 
2. Define all abbreviations 
SUMMARY OF TEST METHODS: 
1. Brief outline of each method  
2. Brief statement of each test method. 
SIGNIFICANCE IN USE: 
1. Relevance in meaning of each test method 
2. Practical use of each test method. 
3 
 
METHODS: 
1. TMA 
2. UV 
PROCEDURE: 
1. Describe the successive steps of the procedure for each technique 
RESULTS: 
1. List all equations 
2. Specify the significant figures 
REFERENCES: 
1. References to publications supporting or providing information 
2. Key words: identify words terms phrases 
CONCLUSIONS: 
1. Summarize all data collected  
2. Compare the data from different methods  
3. Site all relevant information. 
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CHAPTER I 
 
INTRODUCTION 
A recent paper by Qureshi
1
 goes directly to the problem in the development and 
validation of drug dissolution (disintegration of oral solid dose tablets and capsules). It is 
pointed out that dissolution tests used as quality control testing (QC) can discover 
variations in product formulations which are not related directly to drug release in 
humans i.e. the state of bio-availability. Further observed deviations from expected drug 
delivery properties do not indicate below average drug release in humans. Quality control 
tests may also result in false negatives. What is needed is a test based on bio-relevancy. 
Qureshi recommends a USP Paddle Apparatus
2
 to simulate physical activity of 
gastrointestinal tract physiology. An in vitro method must be product independent. His 
crescent-shaped paddle test achieved the objective of product independence while 
simplifying method development and testing
3
.  
      An important feature of drug disintegration is to comprehend the effect of drug-
excipient interaction. Drebushchak et al used thermo analytical methods TGA and DSC 
along with X-ray Diffraction analysis to evaluate the dehydration and decomposition of 
various drugs. It was observed that the crystal structure of cellulose after heating did not 
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change but Chitosan did contract changing its disintegration properties
4
. Solid dose 
technology was reviewed by Wesolowski
5
 based on DSC and TGA characterization. 
They studied tablet disintegration and effect of grinding and observed that bioavailability 
varied. Cracks and altered appearances also caused disintegration variations. Mechanical 
preparation of drugs was used to vary dispersion properties of drugs with 
polyvinylpyrrolidone and polyethylene glycol as excipients. Higher apparent solubility 
and dissolution rates were measured by this innovative mechanical technique, i.e. applied 
stress caused the observed changes
6
. Gomes, Souza and Macedo studied the thermal and 
dissolution kinetics of Ampicillin drugs
7
. The dissolution profiles were obtained using 
USP 23 method. The results of the study showed a good correlation between the 
Kitazawa rate constant and the thermal decomposition reaction rate constants. This 
correlation can be used to confirm pharmaceutical equivalence between reference and test 
products.  
There is an ongoing need to develop a better understanding of how solid dose tablets 
initially disintegrate and proceed to the final state of disintegration in an aqueous medium 
of known pH. Our new innovative Isothermal Thermal Mechanical Analysis (IsoTMA) 
method established the relevancy and range of drug dissolution by in vitro examination of 
Olanzapine®, an “orally disintegrating drug” which disintegrates in 18 seconds at a 
dimensional rate change of approximately 6 millimeters/min. Conversely Abilify® has an 
IsoTMA disintegration time of 60-70 minutes and a much slower rate measured in units 
of microns/min. Dr. Riga and Alexander introduced this IsoTMA method internationally 
at the International Congress on Thermal Analysis and Calorimetry (ICTAC) Conference 
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in Denmark
8
. They reported a real world disintegration evaluation that correlated well 
(R
2
=0.92) with the Iso TMA method (Figure 1).  
Williams, Alexander and Riga examined a wide variety of rapidly disintegrating tablets 
by IsoTMA
9-10
. They observed a good correlation between the United States 
Pharmacopeia (USP) dissolution method
11
 and the IsoTMA technique with consistent 
results for enteric coated tablets. However the USP method
12
 only deals with the final 
disintegration of the tablet while this IsoTMA method reveals the initial time and rate of 
disintegration. One assumes the dimensional stability, as monitored by IsoTMA, can be 
correlated to solid dose tablet disintegration in the throat, stomach or intestines. To-date, 
we are confident that there is a good relationship with this new analytical tool and drug 
delivery since, in a number of cases, the drug uptake at pH=1 was correlated with 
IsoTMA and ultraviolet spectroscopy. 
The objectives of this study are to evaluate formulated tablet drugs by their disintegration 
times (min) and dimensional stability rates (millimeters/min = mm/min or microns/min = 
µm/min). These dimensional stability rates are considered to represent the disintegration 
rates of the formulated tablets. Initially, we had hoped to observe disintegration 
mechanisms that might involve swelling in an aqueous fluid ultimately followed by 
disintegration in one or more steps. Variables in this study were different drug/excipients 
combinations, different pH and temperature.  
Tablets disintegrate and release their active drug while structurally changing. Some 
tablets expand and thereby allow the active ingredient to be released. Other tablets swell 
and then disintegrate either rapidly or over a period of time. Measured disintegration 
times can statistically distinguish between drugs disintegrating in less than 1 minute, 5 to 
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10 minutes and those disintegrating in more than 30 minutes. The IsoTMA method can 
identify the drug delivery process as orally occurring over 15-30 seconds, gastrically over 
2- 30 minutes and intestinally over 30-90 minutes. The percent relative error for IsoTMA 
measured disintegration times was approximately10-20% and is probably due primarily 
to non-uniformity of the tablet surface with its curvature and embossed letters.  
The % relative error of the disintegration rate (mm/min) varied more widely than the 
disintegration time, with a value of 20-30%. Factors to improve the precision and 
accuracy of TMA (relative to the standard APA method) will be discussed. 
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TABLETS:  
Tablets are solid dosage forms containing one or more active ingredients. They are 
obtained by single or multiple compression (in certain cases they are moulded) and may 
be uncoated or coated. They are usually intended for oral administration, but preparations 
for alternative applications, such as implants, solution-tablets for injections, irrigations, or 
for external use, vaginal tablets, etc., are also available. These preparations may require a 
special formulation method of manufacture. The different categories of tablet that exist 
include soluble tablets, effervescent tablets, tablets for use in the mouth, and modified-
release tablets. Unless otherwise specified in the individual monograph, tablets are 
normally circular in shape, and their surfaces are flat or convex. Tablets may have lines 
or break-marks, symbols, or other markings. They should be sufficiently hard to 
withstand handling, including packaging, storage, and transportation, without crumbling 
or breaking. 
Tablets may contain excipients such as diluents, binders, disintegrating agents, glidants, 
and lubricants, substances capable of modifying the behavior of the dosage forms and the 
active ingredient in the gastrointestinal tract, coloring matter, and flavoring substances. 
When such excipients are used, it is necessary to ensure that they do not adversely affect 
the stability, dissolution rate, bioavailability, safety, or efficacy of the active 
ingredient(s); there must be no incompatibility between any of the components of the 
dosage form. 
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CAPSULES:  
Encapsulation refers to a range of techniques used to enclose medicines in a relatively 
stable shell known as a capsule, allowing them to, for example, be taken orally or be used 
as suppositories. The two main types of capsules are: 
 Hard-shelled capsules, which are normally for dry, powdered ingredients or 
miniature pellets or tablets;  
 Soft-shelled capsules, primarily used for oils and for active ingredients that are 
dissolved or suspended in oil.  
Both of these classes of capsules are made from aqueous solutions of gelling agents like: 
Animal protein mainly gelatin; Plant polysaccharides or their derivatives like 
carrageenans and modified forms of starch and cellulose. Other ingredients can be added 
to the gelling agent solution like plasticizers such as glycerin and or sorbitol to decrease 
the capsules hardness, coloring agents, preservatives, disintegrants, lubricants and surface 
treatment. 
DISINTEGRATION:  
Disintegration is defined as that state in which no residue of the tablet or capsule remains 
on the screen of the apparatus or, if a residue remains, it consists of fragments of 
insoluble coating of the tablets or of capsule shells or is a soft mass with no palpable 
core. If discs have been used with capsules, any residue remaining on the lower surface 
of the discs consists only of fragments of shells. 
10 
 
DISSOLUTION: 
Dissolution is a standardized method for measuring the rate of drug release from a dosage 
form. The principle function of the dissolution test may be summarized as follows:                                       
• Optimization of therapeutic effectiveness during product development and stability 
assessment. 
• Routine assessment of production quality to ensure uniformity between production lots. 
• Assessment of „bioequivalence‟, that is to say, production of the same biological 
availability from discrete batches of products from one or different manufacturers. 
• Prediction of „in-vivo‟ availability, i.e. bioavailability 
DISSOLUTION TESTING  
In a recently published paper in Pharmaceutical Technology, Gene Knapp explains why 
FDA has become involved in dissolution testing
13 
briefly; they feel that in vitro 
dissolution testing can help the development of formulations that may present potential 
bioequivalence problems. They further believe that once a formulation has been shown to 
be bioavailable, dissolution testing is of great value in assuring lot-to-lot bioequivalence. 
Many dissolution apparatuses that have been proposed for in vitro testing of solid drug –
dosage forms, FDA has chosen to concentrate on three apparatus: The USP rotating 
basket apparatus,
 14
 the USP paddle apparatus,
 15 
and the former two have achieved 
official recognition by the USP. The National Center for Drug Analysis (NCDA) has 
been conducting routine dissolution tests with some techniques evolving from the basket 
method and paddle method and gives good results. In vitro dissolution testing, as applied 
to solid-dosage drug forms measures the amount of drug dissolved in a known volume of 
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liquid medium at a predetermined time, using a specified apparatus designed to carefully 
control the parameters of dissolution testing. The amount of drug dissolved may be 
determined at one time  
DEAERATION: 
In our laboratory, deionized water is routinely used to prepare large batches of dissolution 
medium. Water emerges from the deionizer below room temperature and under pressure, 
and thus will be supersaturated with air. This medium is used in test under 37
o
C. During 
this testing excess air will manifest itself as tiny bubbles and this affects the dissolution 
rate. Air may be partially removed by boiling and cooling the water, by spraying the 
water into a large vessel under vacuum. If a large quantity of medium is prepared before 
it is implemented, then it is best to test the medium and bring the temperature to 37
o
C and 
then use the medium. 
TEMPERATURE  
Temperature of the dissolution medium in the vessels should be checked before the test is 
started. A dissolution apparatus is used with a constant temperature bath of 37
o
C. If the 
temperature of the bath is less than 37
o
C heat the medium until it attains the required 
temperature. 
VOLUME: 
The amount of drug dissolved during testing is determined from its concentration in the 
dissolution medium, therefore the total volume of dissolution present in the system at a 
time the sample is withdrawn must be known. Relatively large volumes, in the range of 
500-1000 ml. are used in the dissolution test. Certain amounts of the samples are taken at 
given intervals. we have to be sure the total amount of the dissolution medium must be 
12 
 
constant before and after taking the samples so we have to put the same amount of 
dissolution medium in the bath after we take sample solution from the bath to test how 
much amount of the drug dissolved in the medium. 
RATE OF AGITATION: 
The rate of agitation and times of aliquoting will be specified in the dissolution test 
methodology. Ideally these parameters will have been selected on the basis of some 
correlation with in vivo data.  
The rate of agitation, usually from 50 to 150 rpm, will govern how quickly a solid dosage 
form will disintegrate or dissolve in specified volume of dissolution medium. From the 
time the drug begins to dissolve until dissolution is complete, concentration gradients are 
present in the dissolution medium. These concentration gradients depend on the rate of 
agitation: as the rate of agitation increases the gradient becomes less pronounced.  
STANDARD SOLUTION: 
In the analysis, the filtrate will be compared to standard solution. It is difficult to know 
the amount of standard solution required to dissolve in the medium. Usually we take 
large amount of standard solution and dissolve in small amount of water-miscible 
solvent. An aliquot of this stock solution is diluted to final volume with the dissolution 
medium. The presence of a small amount of water-miscible solvent in the standard 
solution should have no effect on the analysis. To confirm this, several standard solutions 
of different strengths should be prepared each of the standard solutions should be diluted 
in the dissolution medium such that each final solution has the same amount of drug 
content.  
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STIRRING CONTROL: 
Apparatus should be adjusted with a variable speed usually 100 rpm speed is preferred in 
the spindle apparatus method. Initially before we start the experiment the speed must be 
adjusted to 25 rpm after it attains the speed the speed must be increased to 50 and then to 
100 rpm. 
                                                            
USP PADDLE METHOD 
In this method usually the solid dosage forms that tend to float should be weighed and the 
metal paddle that is inert to medium. There should be minimal movement of solid dosage 
forms under the paddle until the disintegration occurs. Excessive movement of the solid 
dosage form gives higher dissolution results. The paddle methodology in USP specifies 
that, ideally the upper portion of the vessel must be cylindrical and bottom would be 
perfect hemisphere. There are two shafts available for this method, one is a coated 
stainless steel shaft and other is a glass shaft. Preferred is the stainless steel shaft.  
In the USP method the paddle shaft will be centered within 0.2 cm of the center line of 
the vessel the shaft shall rotate without perceptible wobble, and the bottom of the paddle 
shall be 2.5cm from the lowest inner surface. Shaft rotation is maintained within the 
nominal value. Temperature is maintained at 37
o
C. 
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LABORATORY PROCEDURE FOR THE PADDLE METHOD: 
Before starting the test, turn the motor and, place the dissolution medium into the vessel 
and measure the temperature. If the temperature is below 37
o
C then raise the temperature 
of the medium to 37
o
C and the speed of the motor must be 100 rpm. Drop the tablet or 
capsule into the vessel, one at point near the wall of the vessel. After the specific periods 
of time withdraw a sample using a glass syringe and membrane filter device for 
subsequent filtration usually the membrane filter device is attached to a syringe and 
aliquot are collected. The aliquots are collected at specific time intervals as 1, 5, 10, 15, 
20, 25, and 30 min until the whole dosage form is dissolved in the medium the resulted 
aliquots are tested. 
Some of the tablets that are orally disintegrating tablets, for these dosage forms the 
aliquots are collected at initial start of the experiment, middle and at the end of the 
experiment eg: Zyprexa tablet dissolves in 18-20 sec so we have take the aliquots at 1, 
10, and 20 sec. 
Dissolution tests are critical and difficult to carry out properly. If one is to obtain correct 
results, care and attention must be given to those aspects that have identified as crucial.  
15 
 
THERMAL MECHANICAL ANALYSIS (TMA) 
Thermal Mechanical Analysis (TMA) is one of a group of techniques of Thermal 
Analysis (TA). The terminology of thermal analysis is recommended by the International 
Confederation of Thermal Analysis and Calorimetry (ICTAC). Terminologies have been 
redefined to provide consistency amongst the numerous thermal analysis techniques
16
. In 
particular TMA has been classified as a method of the Thermomechanometry (TM) 
technique. 
Thermomechanometry is the measurement of a change of a dimension or a mechanical 
property of the sample while it is subjected to a temperature regime. An associated 
thermo analytical method is thermo mechanical analysis. A special related technique is 
thermodilatometry (TD), the measurement of a change of a dimension of the sample with 
negligible force acting on the sample while it is subjected to a temperature regime. The 
associated thermo analytical method is thermodilatometry analysis (TDA). TDA is often 
referred to as zero force TMA. The temperature regime may be heating, cooling at a rate 
of temperature change that can include stepwise temperature changes, linear rate of 
change, temperature modulation with a set frequency and amplitude, free (uncontrolled) 
heating or cooling, or maintaining a constant increase in temperature. The sequence of 
temperatures with respect to time may be predetermined (temperature programmed) or 
sample controlled (controlled by a feedback signal from the sample response). 
Thermomechanometry includes several variations according to the force and the way the 
force is applied. Static force TM (sf-TM) is, when the applied force is constant; 
previously called TMA with TD as the special case of zero force. Dynamic force TM (df-
TM) is, when the force is changed as for the case of a typical stress–strain analysis; 
16 
 
previously called TMA with the term dynamic meaning any alteration of the variable 
with time, and not to be confused with dynamic mechanical analysis (DMA). Modulated 
force TM (mf-TM) is when the force is changed with a frequency and amplitude; 
previously called DMA. The term modulated is a special variant of dynamic, used to be 
consistent with modulated temperature differential scanning calorimetry (mt-DSC) and 
other situations when a variable is imposed in a cyclic manner
17
. The paper by Seyler and 
Earnest gives information about development and testing of a method for TMA 
temperature calibration. They report on the experimental results of round robin that 
included seven labs. Although interlaboratory results vary by several degree, the bias 
(accuracy) in these measurements was less than 0.1
o
C when corrections for temperature 
linearity in each measurements was included in analysis. 
MATERIAL PROPERTIES AND THERMOMECHANICAL MEASUREMENTS: 
TMA and TDA are typically used in assigning temperature or determining the coefficient 
of linear thermal expansion by linear thermal expansion dialometry. The techniques 
associated with TMA are broadly applicable in material science and are used in 
characterizing liquids polymers and inorganic materials. Van krevelen‟s18 classification 
of material properties describe the many applications of many thermo mechanical 
methods. Table provides comprehensive overview of various applications of 
thermomechanical methods. Some of the materials studied such as polymers and 
plasticizers are briefly explained in their corresponding plots with different parameters. 
TMA Comprises a valuable set of techniques for characterizing a variety of bulk and 
molecular properties in virtually any material. While Thermomechanical analyzers are 
most often used in penetration or expansion modes, many instruments can be modified to 
17 
 
execute a variety of far more sophisticated experiments. Three of these techniques have 
been adopted by ASTM
 [19, 20-22]
 while quite sensitive for some applications, 
Thermomechanical methods
 [23]
 appear best suited to a complimentary role in research. 
They are used in analyzing the materials and data and great care must be taken in 
applying the TMA techniques. However, TMA serves as testimony to its versatility and 
utility for characterizing materials from the laboratory to production. 
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ULTRAVIOLET SPECTROPHOTOMETRY (UV) 
Ultraviolet-visible spectroscopy or ultraviolet-visible spectrophotometry (UV-Vis or 
UV/Vis) refers to absorption spectroscopy in the ultraviolet-visible spectral region. This 
means it uses light in the visible and adjacent (near-UV and near-infrared (NIR)) ranges. 
The absorption in the visible range directly affects the perceived color of 
chemicals involved. In this region of the electromagnetic spectrum, 
molecules undergo electronic transitions. This technique is complementary 
to fluorescence spectroscopy, in that fluorescence deals with transitions from the excited 
state to the ground state, while absorption measures transitions from the ground state to 
the excited state.
[24] 
BEER-
 
LAMBERT LAW: 
The method is most often used in a quantitative way to determine concentrations of an 
absorbing species in solution, using the Beer-Lambert law: 
 − , 
Where A is the measured absorbance, I0 is the intensity of the incident light at a 
given wavelength, I is the transmitted intensity, L the path length through the sample, 
and c the concentration of the absorbing species. For each species and wavelength, ε is a 
constant known as the molar absorptivity or extinction coefficient. This constant is a 
fundamental molecular property in a given solvent, at a particular temperature and 
pressure, and has units of 1 / M * cm or often AU / M * cm. 
The absorbance and extinction ε are sometimes defined in terms of the natural 
logarithm instead of the base-10 logarithm. 
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The Beer-Lambert Law is useful for characterizing many compounds but does not hold as 
a universal relationship for the concentration and absorption of all substances. A 2nd 
order polynomial relationship between absorption and concentration is sometimes 
encountered for very large, complex molecules such as organic dyes (Xylenol 
Orange or Neutral Red, for example). 
APPLICATIONS: 
 UV/VIS spectroscopy is used in the quantitative determination of solutions of 
transition metal ions and highly conjugated apparatus  
 It is used to know the concentration of the sample at desired wave length  
 UV can also be used as detector for HPLC 
 UV is used to determine the type of the bonds present in the molecule at particular 
absorption which are valuable in determining functional group in a compound. 
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DRUGS STUDIED BY TMA: 
ABILIFY: 
Scientific name of Abilify is (Aripiprazole) which is an Anti Psychotic drug and 
antidepressant used in the treatment of schizophrenia, bipolar disorder and clinical 
depression; it is mostly used for acute manic and mixed disorder associated with bipolar 
disorder in adults
 [25]
. The IUPAC name of Aripiprazole is 7-{4-[4-(2,3-
dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one. 
 
 
 
The Chemical Formula of Abilify is C17H27Cl2N3O2 which has molecular mass of 448.35 
and has Bio-availability of 87%. Abilify is soluble in water and sulphuric acid 
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AMOXICILLIN:  
Amoxicillin is a moderate - spectrum, bacteriolytic, β-lactum antibiotic used to treat 
bacterial infections caused by susceptible microorganisms. It is the drug of choice 
because it is well absorbed. Amoxicillin in trihydrate form is available in capsule form 
and tablet, suspension for oral use and sodium salt for intravenous administration. It is 
one of the most common antibiotics prescribed for children  
 
The IUPAC name of amoxicillin is (2S,5R,6R)- 6-{[(2R)-2-amino- 2-(4-hydroxyphenyl)- 
acetyl]amino}- 3,3-dimethyl- 7-oxo- 4-thia- 1-azabicyclo[3.2.0] heptane- 2-carboxylic 
acid. The chemical name of Amoxicillin is C16H19N3O5S which has a molecular weight of 
365.4gm/mol has a bio-availability of 95% which is readily soluble in mouth. 
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AMANTADINE 
Amantadine is chemically designated as 1-adamantamine hydrochloride. It is available in 
capsules which are intended for oral use. It is used to treat Parkinson‟s disease; drug 
induced extra pyramidal syndromes and Akathisia. It is also used to treat the respiratory 
infections caused by influenza A virus (flu)
 [26, 27, 28] 
 
Amantadine is frequently used to treat characteristic fatigue often experienced by patients 
with Multiple sclerosis; low dose of amantadine is used to treat attention-deficit 
hyperactivity disorder. It is stable and freely soluble in water and alcohol and in 
chloroform. The IUPAC name of amantadine is adamantan-1-amine has a chemical 
formula of C10H17N and has a molecular mass of 151.240gm/mol and is well absorbed. 
Amantadine has inactive ingredients such as   Yellow Iron Oxide, gelatin, glycerin, 
hydrogenated vegetable oil, lecithin-bleached, soybean oil, sorbitol, sorbitan, mannitol, 
titanium dioxide, white beeswax, vegetable shortening, simethicone and iron oxide (black 
imprint ink). 
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AMBIEN 
The scientific name of ambien is Zolpidem used for short term treatment of insomnia. It 
belongs to class called sedative-hypnotics. It is a short acting nonbenzodiapine hypnotic 
which works by slowing the activity in the brain to sleep. it comes as a tablet which is a 
extended release tablet taken orally. 
 
 
Zolpidem is sparingly soluble in water, alcohol and propylene glycol, IUPAC name of 
Zolpidem is N,N,6-Trimethyl-2-(4-methylphenyl)-imidazo[1,2-a]pyridine-3-acetamide 
has a chemical formula C19H21N3O has a molecular weight of 764.88. Each Ambien 
tablet includes the following inactive ingredients: hydroxypropyl methylcellulose, 
lactose, magnesium stearate, micro-crystalline cellulose, polyethylene glycol, sodium 
starch glycolate, and titanium dioxide. The 5 mg tablet also contains FD&C Red No. 40, 
iron oxide colorant, and polysorbate 80. The bioavailability of Zolpidem is 70% orally 
and 90% in plasma  
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ASPIRIN 
 
Scientific name of Aspirin is Acetyl salicylic acid is a salycilate drug often used as 
analgesic to treat minor aches and pains, as an antipyretic to reduce the fever, and as an 
anti-inflammatory medication. It belongs to class of Non Steroidal Anti-inflammatory 
Drugs (NSAID‟s). It is easily soluble in water  
 
The IUPAC name of aspirin is 2-acetoxybenzoic acid has a chemical formula of C9H8O4. 
Its molecular weight is 180.157g/mol. Its melting point is 135
0
c. its bioavailability is 
rapid and completely absorbed. Its solubility in water is 3gm/ml. it is one of the first line 
drugs used for treatment of migraine and higher amount of aspirin is used for treatment of 
heart diseases. It is white crystalline acidic compound rapidly decomposes in ammonium 
acetate and citrates carbonates and hydroxides 
 
25 
 
 
COLDACT 
Coldact it comes in capsules which is taken orally, it is a complex capsules which 
contains three active ingredients Chlorpheniramine 
Maleate+Acetaminophne+Phenylephrine hydrochloride. it is anti-catahrrhal drug with 
analgesic, decongestant and antihistaminic actions, effectively  prescribed for cold, 
sneezing, rhinorrhea and any type of rhinitis. It is long acting drug.  Acetaminophen: 
IUPAC name is  N-(4-hydroxyphenyl)acetamide, chemical formula is C8H9NO2 
 
 
 
CHLOROPHENIRAMINE MALEATE: IUPAC name is 3-(4-chlorophenyl)-N,N-
dimethyl- 
3-pyridin-2-yl-propan-1-amine, chemical formula is C16H19ClN2 
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PHENYLEPHERNINE HCl 
It is used to relieve nasal discomfort caused by cold allergies and hay fever. It is also used 
to relieve sinus congestion and pressure.  
 
 
IUPAC name of phenylephernine hydrochloride is Benzenemethanol,3-hydroxy-a-
[(methylamino)methyl]-,hydrochloride(R)-. (-)-m-Hydroxy-a-
[(methylamino)methyl]benzyl alcohol hydrochloride [61-76-7]. It s chemical formula is 
C9H13NO2. It  has a molecular mass of 167.205gm/mol. Its bioavailability is 38% in GI 
tract. Its melting point range is from 140
0
-145
0
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HYTRIN 
 
The scientific name of hytrin is Terazosin Hydrochloride is a selective alpha antagonist 
used for the treatment of enlarges prostate gland, benign prostatic hyperplasia (BPH) 
which includes difficulty in urination and painful urination and urinary frequency and 
urgency and hypertension. So it is the drug of choice for men with hypertension and 
enlarged prostate gland. It belongs to class alpha-andrenergic blockers.  
 
The IUPAC name of Hytrin is RS)-Piperazine, 1-(4-amino-6,7-dimethoxy-2-
quinazolinyl)-4-[(tetra-hydro-2-furanyl)carbonyl]-, monohydrochloride, dihydrate. hytin 
is a white crystalline powder which is readily soluble in water and isotonic solutions and 
has a molecular weight of 459.93. These tablets are supplied in different strength 1mg, 2 
mg, 5mg, 10 mg. the inactive ingredients are vary depend on the weight of the tablet. 
1 mg tablet: corn starch, lactose, magnesium stearate, povidone and talc. 
2 mg tablet: corn starch, FD&C Yellow No. 6, lactose, magnesium stearate, povidone and 
talc. 
5 mg tablet: corn starch, iron oxide, lactose, magnesium stearate, povidone and talc. 
10 mg tablet: corn starch, D&C Yellow No. 10, FD&C Blue No. 2, lactose, magnesium 
stearate, povidone and talc. 
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HALOPERIDOL 
Haloperidol is a typical Anti psychotic drug belongs to class of bytrophenone. It is used 
to treat schizophrenia and acute psychotic states and delirium. It is also used to control 
motor tics. Verbal tics and tourette‟s disorder. It also used to treat explosive behavior and 
hyper activity in children.   
 
 
 
The IUPAC name of haloperidol is 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-
fluorophenyl)-butan-1-one, chemical formula is C21H23ClFNO2 which has a molecular 
weight of 375.9g/mol. The bioavailability of haloperidol is 60%-70%. The melting point 
of Haloperidol is 151.5
0
c. its solubility is 14mg/l and it is bioavailability is 60% orally. 
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LEXAPRO 
The scientific name of lexapro is Escitalopram Oxalate. Lexapro is mainly used as 
antidepressant which belongs to class Selective Serotonin Reuptake Inhibitors (SSRI). It 
is used to treat major disorders depression 
 
 
 
The IUPAC name of Lexapro is S-(+)-1-[3-(dimethyl-amino)propyl]-1-(p-fluorophenyl)-
5-phthalancarbonitrile oxalate, chemical formula is C20H21FN20.C2H2O4, and its  
molecular weigh is 414.40 gm/mol. lexapro occurs as white-yellow powder which is 
soluble in methanol, isotonic saline solution and slightly soluble in water , and its 
bioavailability is 80%.   The tablets also contain the following inactive ingredients: talc, 
croscarmellose sodium, microcrystalline cellulose/colloidal silicon dioxide, and 
magnesium stearate. The film coating contains hypromellose, titanium dioxide, and 
polyethylene glycol. 
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PAROXETINE HYDROCHLORIDE 
 
Paroxetine is a anti depressant which belongs to class SSRI. Paroxetine is used to treat 
major depression, obsessive-compulsive disorder (OCD), and panic, social anxiety, 
general anxiety, post- traumic stress disorder (PTSD), generalized anxiety disorder 
(GAD), premenstrual dysphoric disorder (PMDD). 
 
The IUPAC name of Paroxetine is (-)-trans-4R-(4'-fluorophenyl)-3S-[(3',4'-
methylenedioxyphenoxy) methyl] piperidine hydrochloride hemihydrate. Its empirical 
formula is C19H20FNO3• HCl• 1/2H2O. It has a molecular weight of 374.80gm/mol. The 
melting point of Paroxetine ranges from 120
0
-138
0
c. the solubility of Paroxetine is 
5.4mg/ml. the bioavailability is completely absorbed in GI tract . the inactive ingredients 
of Paroxetine consist of dibasic calcium phosphate dihydrate, hypromellose, magnesium 
stearate, polyethylene glycols, polysorbate 80, sodium starch glycolate, titanium dioxide, 
and 1 or more of the following: D&C Red No. 30 aluminum lake, D&C Yellow No. 10 
aluminum lake, FD&C Blue No. 2 aluminum lake, FD&C Yellow No. 6 aluminum lake.    
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RISPERDAL 
Risperidone is a typical antipsychotic drug belongs to class of benzisoxazole used for 
treatment of schizophrenia, shizo affective disorder, bipolar disorder, autism. It is also 
used as control drug for treatment of tourett syndrome, obsessive compulsive disorder, 
eating disorder, disruptive behavior disorder, depression. 
  
 
 
The IUPAC name of Risperidone is 4-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-
piperidyl]ethyl]-3-methyl-2,6-diazabicyclo[4.4.0]deca-1,3-dien-5-one. Its empirical 
formula is C23H27FN4O2 has a molecular weight of 410.485gm/mol. The bioavailability 
of the drug 70% orally.for the orally disintegrating tablets the bioavailability is 90%. It is 
insoluble in water and soluble in 0.1 HCl, methylene chloride and methanol. 
RISPERDAL® Tablets are available in 0.25 mg (dark yellow), 0.5 mg (red-brown), 1 mg 
(white), 2 mg (orange), 3 mg (yellow), and 4 mg (green) strengths.  
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Risperdal® tablets contain the following inactive ingredients: colloidal silicon dioxide, 
hypromellose, lactose, magnesium stearate, microcrystalline cellulose, propylene glycol, 
sodium lauryl sulfate, and starch (corn). The 0.25 mg, 0.5 mg, 2 mg, 3 mg, and 4 mg 
tablets also contain talc and titanium dioxide. The 0.25 mg tablets contain yellow iron 
oxide; the 0.5 mg tablets contain red iron oxide; the 2 mg tablets contain FD&C Yellow 
No. 6 Aluminum Lake; the 3 mg and 4 mg tablets contain D&C Yellow No. 10; the 4 mg 
tablets contain FD&C Blue No. 2 Aluminum Lake. RISPERDAL® M-TAB® Orally 
Disintegrating Tablets are available in 0.5 mg (light coral), 1 mg (light coral), 2 mg 
(coral), 3 mg (coral), and 4 mg (coral) strengths.  
Risperdal® M-TAB® Orally Disintegrating Tablets contain the following inactive 
ingredients: Amberlite® resin, gelatin, mannitol, glycine, simethicone, carbomer, sodium 
hydroxide, aspartame, red ferric oxide, and peppermint oil. In addition, the 2 mg, 3 mg, 
and 4 mg RISPERDAL® M-TAB® Orally Disintegrating Tablets contain xanthan gum. 
The melting point of Risperidone is 170
0
c.  The Experimental solubility of Risperidone is 
2.8mg/ml.  
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ROZEREM 
 
Rozerem (ramelton) is a sedative which causes sleep it is mostly used for insomnia. It 
belongs to class melatonin receptor agonist. Rozerem (ramelteon) is an orally active 
hypnotic chemically designated as (S)-N-[2-(1,6,7,8-tetrahydro 2H-indeno-[5,4-b]furan-
8-yl)ethyl]propionamide 
 
The chemical formula of Rozerem is C16H21NO2, has a molecular weight of 
259.34gm/mol. Rozerem is freely soluble in organic solvents, such as methanol ethanol. 
Soluble in 1-octanol, acetonitrile and very slightly soluble in water. The melting point of 
Rozerem is 113-115
0
c. each Rozerem tablet includes the following inactive ingredients: 
lactose monohydrate, starch, hydroxypropyl cellulose, magnesium stearate, 
hypromellose, copovidone, titanium dioxide, yellow ferric oxide, polyethylene glycol 
8000, and ink containing shellac and synthetic iron oxide black. 
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SERTRALINE 
Sertraline hydrochloride is an antidepressant of selective serotonin reuptake inhibitor 
(SSRI). Sertraline is used to treat major depression obsessive compulsive disorder, panic 
disorder, posttraumatic stress disorder and social anxiety disorder.  
 
 
The IUPAC name if Sertraline is (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-
methyl-1-naphthalenamine hydrochloride. The chemical formula is C17H17NCl2.HCl. the 
molecular weight of Sertraline is 342.70gm/mol. Sertraline is a white crystalline powder 
which is slightly soluble in water and isopropyl alcohol and sparingly soluble in ethanol. 
The bioavailability of Sertraline is 44% and melting point of Sertraline is 246-249
0
c. the 
inactive ingredients of Sertraline is dibasic calcium phosphate dihydrate, D & C Yellow 
#10 aluminum lake (in 25 mg tablet), FD & C Blue #1 aluminum lake (in 25 mg tablet),  
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FD & C Red #40 aluminum lake (in 25 mg tablet), FD & C Blue #2 aluminum lake (in 50 
mg tablet), hydroxypropyl cellulose, hypromellose, magnesium stearate, microcrystalline 
cellulose, polyethylene glycol, polysorbate 80, sodium starch glycolate, synthetic yellow 
iron oxide (in 100 mg tablet), and titanium dioxide. 
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ZYPREXA 
Zyprexa (Olanzapine) is a typical antipsychotic used for the treatment of schizophrenia 
and bipolar disorder, obsessive compulsive disorder, panic disorder, social anxiety 
disorder, posttraumatic stress disorder it belongs to class thienobenzodiazopene. 
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CYMBALTA 
Cymbalta (duloxetine) is a anti-Psychotic drug is a serotonin-norepinephrine reuptake 
inhibitor it is effective for major depression disorder and general anxiety disorder and it 
also treats chronic pain disorder. It belongs to class tri cyclic anti depressants  
 
The IUPAC name of Cymbalta is (+)-(S)-N-methyl-β-(1-naphthyloxy)-2-
thiophenepropylamine hydrochloride. The chemical formula is C18H19NOS•HCl. The 
molecular weight of Cymbalta is 333.88gm/mol. Duloxetine hydrochloride is a white to 
slightly brownish white solid, which is slightly soluble in water. Each capsule is enteric 
coated tablets. The inactive ingredients of Cymbalta are FD&C Blue No. 2, gelatin, 
hypromellose, hydroxypropyl methylcellulose acetate succinate, sodium lauryl sulfate, 
sucrose, sugar spheres, talc, titanium dioxide, and triethyl citrate. 
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DEPAKOTE 
Depakote (valproic acid) it is used in mood stabilizing disorder epilepsy bipolar disorder 
major depression.  It is also used to treat migraine and schizophrenia. 
 
 
 
The IUPAC name of Depakote is sodium hydrogen bis(2-propylpentanoate). The 
chemical formula of Depakote is NaC8H16O2. The molecular weight of Depakote is 
144.211gm/mol. The bioavailability of Depakote is 90%. The melting point is 222
0
c. the 
inactive ingredients of Depakote are  cellulosic polymers, diacetylated monoglycerides, 
povidone, pregelatinized starch (contains corn starch), silica gel, talc, titanium dioxide, 
and vanillin. 
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BUSPIRONE 
Buspirone is a psychoactive drug which belongs to class piperazine it is used for general 
anxiety disorder  
 
 
The IUPAC name of Buspirone is 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-
azaspiro [4.5]decane-7,9-dione monohydrochloride. The chemical formula is 
C21H31N5O2•HCl. The molecular weight of buspirone is 422mg/mol. Buspirone is white 
crystalline which is soluble in water. The inactive ingredients present in buspirone are 
colloidal silicon dioxide, lactose, magnesium stearate, microcrystalline cellulose, and 
sodium starch glycolate. The melting point of buspirone is 201.5-202.5
0
c. the 
experimental solubility of buspirone is 24mg/l. 
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PALPERIDOL 
Palperidol is a typical anti psychotic drug belong to class benzisoxazole which is 
extended release tablet. It is mainly used to treat schizophrenia  
 
 
The IUPAC name of Palperidol is (±)-3-[2-[4-(6-fluoro-1,2benzisoxazol-3-yl)-1-   
piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4Hpyrido[1,2-a]pyrimidin-4-
one. The chemical formula is C23H27FN4O3 and its molecular weight is 426.69. 
Paliperidone is sparingly soluble in 0.1N HCl and methylene chloride; practically 
insoluble in water, 0.1N NaOH, and hexane; and slightly soluble in N,N-
dimethylformamide. The inactive ingredients of Palperidol are carnauba wax, cellulose 
acetate, hydroxyethyl cellulose, propylene glycol, polyethylene glycol, polyethylene 
oxides, povidone, sodium chloride, stearic acid, butylated hydroxytoluene, hypromellose, 
titanium dioxide, and iron oxides. The bioavailability of Paliperidone is 28%.  
 
 
. 
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CHAPTER II 
 
INSTRUMENTATION AND METHODS 
 
THERMAL MECHANICAL ANALYZER (TMA) 
 
The IsoTMA procedure uses a TA Instruments 942 Thermal Mechanical Analyzer. A 
schematic of this instrument is shown in Figure 2. This TMA measures the displacement 
of a quartz probe that rests on the surface of the sample. As the sample changes 
dimensions due to swelling or dissolution, the position of the probe rises or falls 
accordingly. This probe displacement is measured electronically by a transformer and, 
after calibration, is recorded as height changes of the probe per unit time.   
To perform these experiments, the 2 mm diameter probe is initially zeroed on the empty 
quartz sample stage. Then the tablet is placed on the stage, the probe lowered onto the 
surface of the tablet and the tablets initial thickness is measured. After waiting about 2.0 
minutes for equilibrium and a steady signal to be achieved, a time base scan is begun. 
The tablet is then immersed in a fluid of interest (ex. water) by raising a beaker 
underneath the sample that sits on a small laboratory jack. The pH of the deionized water 
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that we used was adjusted to 3, 4, and 7 with pH = 7 being typical. A weight can also be 
placed on top of the probe to improve contact with the surface of the tablet and to 
minimize probe slippage. The applied loads during our tests varied from 0.5 to 10 grams, 
with 1.0 gram being typical. If desired, the beaker of fluid can be placed on a hot plate to 
raise its temperature. For our experiments, the fluid temperature was either 24 or 37
o
C. 
Figure 3 shows a Ritalin tablet, and the quartz probe, before disintegration and while 
disintegrating in the fluid. 
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CHAPTER III 
 
ULTRA VISIBLE SPECTROPHOTOMETER 
Tablet disintegration was studied using TMA, in a 0.1N sulphuric acid as the media.   
After the tablet disintegration the media is collected and filtered using a filter paper so 
that we can see clear solution. The UV spectrophotometer used for the analysis was ___. 
Before performing the uv analysis of the desired solution we have take blank solution 0.1 
N sulphuric acid in the clean cuvet calculate the absorbance of the blank solution. Then 
we have take 1ml of filtered zyprexa solution (stock solution)  perform the uv analysis 
and we have calculate the absorbance and wavelength of the solution if the absorbance is 
more then we have to dilute the solution and again perform the uv analysis of the diluted 
stock solution until we desired absorbance range. The maximum disintegration of the 
tablet occurs at the maximum absorbance. The energy is calculated by equation 
                                             E=hc/λ  
E= energy. 
H= planck‟s constant.  
C =concentration.,λ = wavelength. 
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Figure 1 TMA vs Real World Disintegration Measurements 
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SCHEMATIC DIAGRAM OF TMA  
 
 
 
Figure 2 Schematic Diagram of TMA 
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Modified TMA apparatus  
 
Figure 3 Modified TMA Apparatus 
 
 
 
 
                   RITALIN TABLET BEFORE AND AFTER DISINTEGRATION 
 
                                            
Figure 4 Ritalin Tablet Before and After Disintegration 
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                         Figure 5 Drug Disintegration of Abilify by Iso TMA   
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                           Figure 6: Drug Disintegration of Amantadine Capsule by Iso TMA 
 
 
 
 
 
 
 
 
49 
 
Starting time = zero
3.71min
-1691µm
-1239µm/min
5.17min
-1994µm
931.7µm/min
6.08min
-1741µm
3.412µm/min
6.70min
-1553µm
1474µm/min
7.98min
-588.5µm
2402µm/min
10.80min
31.75µm
-2500
-1500
-500
500
1500
2500
3500
D
e
ri
v
. 
D
im
e
n
s
io
n
 C
h
a
n
g
e
 (
µ
m
/m
in
)
0 5 10
Time (min)
Sample: AMBIBN 10MG TAB
Size:  3.2000 mm
Method: TABLETS
Comment: 1000MG/FLAT PROBE /30 C
TMA
File: C:\AMBIBN.003
Operator: RAO
Run Date: 28-Aug-2009 12:17
Universal V4.5A TA Instruments
 Figure 7: Drug Disintegration of Ambien tablet by Iso TMA 
 
 
 
 
 
 
 
50 
 
Starting Time=zero
4.90min
1293µm/min 7.25min
3904µm/min
24.17min
107.3µm/min
32.84min
193.8µm/min
44.14min
60.99µm/min
Coldact Capsule Release 
Intestines 24 to 44 min
-2000
0
2000
4000
6000
D
e
ri
v
. 
D
im
e
n
s
io
n
 C
h
a
n
g
e
 (
µ
m
/m
in
)
0 10 20 30 40 50 60
Time (min)
Sample: COLDACT capsule
Size:  3.2000 mm
Method: TABLETS
Comment: 1000MG/FLAT PROBE /30 C
TMA
File: C:\080709.003
Operator: MM AND RAO
Run Date: 08-Jul-2009 13:11
Universal V4.5A TA Instruments
 
                              
                                Figure 8: Drug Disintegration of Coldact Capsule by Iso TMA 
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    Figure 9: Drug disintegration of Femhrt tablet by IsoTMA under different ph 5, 7
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                        Figure 10: Drug disintegration of Paroxetine HCl by IsoTMA 
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                                        Figure 11: Drug Disintegration of Ritalin Tablet by ISOTMA 
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                         Figure 12: Drug Disintegration of Risperdal tablet by Iso TMA 
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                   Figure 13: Drug Disintegration of Risperdal 2mg tablet BY IsoTMA 
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                       Figure 14: Drug Disintegration of Risperdal 3mg tablet by Iso tma 
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                      Figure 15: Drug Disintegration of haloperidol tablet by Iso tma 
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                  Figure 16:   Drug Disintegration of lexapro tablet by Iso TMA 
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                               Figure 17: Drug Disintegration of Sertraline tablet by Iso tma 
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                          Figure 18: drug disintegration of Rozerem tablet by Iso tma 
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                            Figure 19: Drug disintegration of Zyprexa tablet by Iso tma 
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Figure 20: Drug Disintegration of Amoxicillin capsule by tma under                  
different temperatures 
Comparison of Capsule Disintegration Rate 
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Respect to Temperature: 25, 32, 37ºC
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Figure 21: Drug disintegration of Amoxicilin capsule with different pH 3,4,7
Comparison of Capsule Disintegration Rate 
(μm/min) and Peak Disintegration Time (min) 
with Respect to pH 3, 4 and 7
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figure 22: Drug Disintegration of Amoxicillin Capsule by Iso tma and visual 
photographic 
methods
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Figure 23: Drug Disintegration of Amoxicillin capsule and their corresponding 
photographs 
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Figure 24: Photographic method of 
Risperdal
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                                                 Figure 25: UV Analysis of Ritalin Tablet 
68 
 
 
 
Figure 26: UV ANALYSIS OF    
RISPERIDAL
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Figure 27: UV Anlysis OF Zyprexa Tablet 
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Table 1 Amoxicillin Capsules /precision of Disintegration behavior 
 
TEST 
NUMBER 
 
T final –  
T Initial 
 
FASTEST 
DISINTEGRATION 
RATE 
(MICRONS/MIN) 
 
TIME TO 
ACHIEVE 
FASTEST 
DISINTEGRATION 
RATE(SECONDS) 
1 64 4100 150 
2 42 4700 180 
3 45 5900 150 
4 45 5800 175 
5 62 3500 160 
6 46 5700 140 
AVERAGE 51 4950 159 
STD. 
DEVIATION 
9 1007 16 
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Table 2: Comparison of drug disintegration of amoxicillin capsule by Iso tma and 
photographic methods. 
 
TEST 
NUMBER 
 
DISINTEG
RATION 
ONSET/SE
CONDS 
(VISUAL/T1
V) 
 
DISINTEGR
ATION 
ONSET/SEC
ONDS 
(TMA/T1T) 
 
DISINTEG
RATION 
COMPLET
E 
(VISUAL/T2
V) 
 
DISINTEG
RATION 
COMPLET
E 
(TMA/T2T) 
 
∆TIME 
T2V-T1V 
 
 
∆TIME 
T2T-T1T 
 
1 120 120 180 150 60 30 
2 150 135 220 170 70 35 
3 150 140 200 180 50 40 
4 150 140 230 210 80 70 
5 150 140 195 190 45 50 
6 130 130 210 180 80 50 
AVERAGE 142 134 206 180 64 46 
STD. 
DEVIATION 
13 8 18 20 15 14 
% ERROR 9 6 9 11 23 30 
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Table 3: DISINTEGRATION TIMES OF AMOXYCILLIN CAPSULES 
 
TEST 
NUMBER 
 
SECONDS 
TO 
MAX. RATE 
pH=3 
 
MAX. RATE 
MICRONS/MM 
pH=3 
 
SECONDS 
TO 
MAX. 
RATE 
pH=4 
 
    MAX. RATE 
 
MICRONS/MM 
pH=4 
 
SECOND
S TO 
MAX. 
RATE 
pH=7 
 
MAX.RATE 
MICRONS/MM 
pH=7 
1 30 11000 33 9800 46 5700 
2 38 10000 45 6000 64 4100 
3 36 9100 42 6300 47 4700 
4 32 7500 41 6500 45 5900 
5 33 7100 38 6600 39 6200 
6 30 7900 32 6800 45 5800 
AVERAG
E 
33 8767 38 7000 48 5400 
STD. 
DEVIATI
ON 
3 1533 5 1399 8 815 
% 
ERROR 
9 17 13 20 17 15 
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Table 4: initial and final drug disintegration of tablets and capsules and their  
target organ 
 
 
 
DRUG INTITIAL                      FINAL TARGET 
ORGAN 
MAX DIS 
RATE 
mm/min 
ABILIFY 1.49 17 STOMACH 2.0 
AMANTADINE 8.63 26.75 STOMACH -0.3 
AMBIBN 3.7 8.8 STOMACH 2.4 
AMOXICILLIN 3.2 8 STOMACH 0.18 
COLDACT 2.9 44.14 INTESTINE 3.9 
HALOPERIDOL 4.89 19.0 STOMACH 36.24 
PAROXTINE 0.6 21.0 STOMACH 0.63 
RISPERDAL 2.5 13.0 STOMACH 1.4 
ROZEREM .5 0.9 MOUTH 0.87 
SERTRALINE 29.15 41.0 INTESTINE 191.04 
ZYPREXA .03 0.23 MOUTH 41.6 
LEXAPRO 0.6 3.0 STOMACH 29.64 
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CHAPTER IV 
 
RESULTS AND DISCUSSIONS 
The IsoTMA results for capsules and tablets are shown in figures  . 
 Abilify® (Aripiprazole) capsule at pH 7 and 24ºC immediately swells and then 
disintegrates over a period of 45-50 minutes (Figure 4). For this type Abilify 10 mg  
tablet the disintegration time is 3.5 min and rate of disintegration 1100 um/min is another 
form of Abilify described above the difference in disintegration is due to capsule vs tablet 
the tablet disintegrates quickly. 
AMANTADINE Capsule (100mg) at pH 7 and 24
0
C disintegrates and swells over a 
period of 25-30 minutes (fig    ). The disintegration peaks are noted at 6.6 min, 10.3 min, 
18.1min these times reflect the dimensional change showing three distinct different times 
which have been corrected to starting time . 
  
AMBIEN tablet 10 mg at pH 7 and temperature 24
0
C disintegrates and swells over a 
period of 7-10 minutes (fig  ). The disintegration of the ambien tablet occurs 1.2 min 
followed by three distinct swelling curves at 2.7 min, 4.2min, 5.5min. their rate of initial 
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disintegration was 1200um/min. the average swelling time 2.7 in, 4.2 min, 5.5 min. the 
average swelling rate is 1300 um/min (932, 1470, 2400) 
Amoxicillin: Amoxicillin capsule  
COLDACT: Coldact capsule at pH 7 and temperature 34
0
C swells and disintegrates 
slowly and again swells and disintegrates over a period of 40 -45 minutes ( fig). Coldact 
capsule initially swells 3 min and 5min at a rate of 1300 and 3900um/min respectively. 
Further swelling characteristics are observed at 22min, 31min, 42min. there are no 
apparent disintegration no structural change of capsule the only observed change of 
capsule is swelling upto 42 min. 
FEMHRT: Femhrt tablet 1 mg at pH5.5 and 7 and temperature 24
0
C slight swelling at 0.2 
min and 0.3 min in pH7 and mechanically collapsed at 0.3 min and was dispersed in 
acidified water in 0.5 min at ph 5.5 again the material swelled initially and disintegrated 
in 0.5 min. the acidified water accelerated the disintegration time frim 0.5 to 0.3 and the 
rate in ph 7 was 2500 and acidified water was 2400. The disintegration time is about 1 
minute.  
HALOPERIDOL: Haloperidol 5mg tablet at pH7 and temperature 24
0
C initially it swells 
at 5min, with rate of 36mm/min. and after it disintegrates step wise at 9min, 10 min, and 
16min over a period of 18-20 min and the average initial rate of disintegration was 
10mm/min, 17mm/min 42um/min. we can see in figure  
PAROXETINE.HCL: Paroxetine tablet 1000mg  at pH 7 and temperature 24
0
C swells 
slowly and then rapidly at 8-9 min the swelling rate is 64um/min. and swelled upto 23 
min this swelling profile implies that the drug is being released not by structural collapse 
but by structural opening. The disintegration time of the Paroxetine is 20-23 minutes  
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 RITALIN® (Methylphenidate.HCl) 10 mg  tablet at pH 7 and 24
o
C, on the other hand, 
did not swell but rather disintegrated stepwise over 32 to 96 minutes (Figure ). The 
dimensional change and derivative (i.e. rate) curves show multiple stages of 
disintegration with three major derivative peaks at (1) 38 ±3 (2) 58 ±2 and (3) 82±2 
minutes. The disintegration rates at  620 and 610um/min corresponding to these three 
major peaks and their standard deviations are (1) 2.1±0.6; (2) 2.8 ±0.8 and (3) 2.0±0.3 
(microns/min).  
 
 
RISPERDAL: Risperdal 0.5 mg and 2mg and 3mg tablets are used for  disintegration at 
pH7 and temperature 24
0
C 
Risperdal 0.5mg tablet swells slowly at 2.5min with a disintegration rate of 173um/min  
and after it disintegrates step wise 5.7 min, 6.2min, 7.0min, 8.1min and the disintegration 
rates are 13mm/min, 17mm/min, 10mm/min, 7200um/min. and the average disintegration 
rate was 9900um/min. we can see in the fig    
Risperdal 2mg tablet swells slowly at 2.5min, 3.15min. with a disintegration rate of 
3088um/min 2439um/min  and after it disintegrates step wise 4..7 min, 5.2min, 7. 5.9min 
and the disintegration rates are 4143um/min, 3652um/min, 2126um/min, 7200um/min. 
and the average disintegration rate was 4500um/min. we can see in the fig 
Risperdal 3mg    tablet swells slowly at 2.1min. With a disintegration rate of 1579um/min   
and after it disintegrates step wise 10.97 min, 12.42min, 15.27min, 16.24min and the 
disintegration rates are 1547um/min, 2642um/min, 15.1mm/min, 49.5mm/min and the 
average disintegration rate was 170mm/min. we can see in the fig 
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LEXAPRO: Lexapro 20mg tablet at pH7 and temperature 24
0
C the tablet disintegrates at 
0.63min with a disintegration rate of 35mm/min and swells at 0.83min with a 
disintegration rate of 26mm/min. we can see in figure ( 
SERTRALINE:  Sertraline 25mg tablet at pH7 and temperature 24
0
C the tablet swells at 
29.6min,33min, 34.7min, 35.7min and disintegration rates are 191mm/min, 173mm/min, 
87mm/min, 160mm/min and disintegration time are32.1min, 35.51min, 35.9minand the 
disintegration rates are 241mm/min, 89mm/min, 155mm/min.we can see in the fig  
ROZEREM: Rozerem 8mg tablet at pH7 and temperature 24
0
C disintegrates in step wise 
time interval of 0.12min, 0.15min, 0.18min, 0.22min and the disintegration rates are 
1348um/min, 1500um/min, 1200um/min, 1100um/min. we can see in fig  
ZYPREXA: Zyprexa tablet at pH7 and temperature 24
0
C when we immerse the tablet in 
the medium it disintegrates so fastly less than 25 sec. we can see in figure   
A comparison of capsule disintegration rates (microns/min) and peak disintegration times 
(min) at different pH (=3, 4, and 7) is shown in figure10. The derivative rate curves 
indicate multiple disintegration processes. The fastest disintegration time was associated 
with pH 3 and the slowest time with pH 7. At pH=7, with the longest disintegration time, 
the fastest dimensional rate of change was 9.8 mm/min after 3.1 minutes. At pH=4, the 
fastest rate was 9.1 mm/min after 2.7 minutes. At pH = 3, there are two derivative peaks 
at 6.6 mm/min after 2.6 min and 4.3 mm/min after 3.3 min. This double peak may be 
related to two different processes of disintegration at lower pH including the dissolution 
of the gel capsule and the delivery of the drug into the surrounding fluid. The pH 
dependence is related to the structure of the gel capsule and the disintegration of the API 
and any excipients.  
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Figure 9 is a comparison of Amoxicillin gelatin capsule dimensional change rates and 
fastest disintegration times as a function of temperature; 25, 32 and 37°C at pH=7. The 
room temperature maximum disintegration rate is 7.0 mm/min at 55 minutes. The 
maximum rate at 32°C is 8.1 mm/min after 6.3 minutes. At 37°C, the maximum rate is 
9.9 mm/min after 2.8 minutes. Clearly temperature has a significant effect on the 
disintegration of the capsule.  
Some other factors to be considered in a future study are residual stresses in the gel 
capsule ends, the uniformity of the gel capsule as a whole, and the particle size of the 
API.  
Statistical analysis of the IsoTMA disintegration of Amoxicillin in a solution of pH 7 at 
37°C is summarized in Table 1. Statistical analysis of the values determined by a 
photographic and the TMA methods are summarized in Table 2.  
Comparisons of the IsoTMA and the optical photography behaviors of the capsule at pH 
4 and 37°C are show in Figure 25. The initial, midrange and final disintegration times can 
be visualized from 1.7 min (100 sec) to 8.0 min (480 sec). 
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CHAPTER V 
 
CONCLUSIONS 
The IsoTMA protocol yields direct information on formulated drug delivery. Some 
tablets disintegrate rapidly in less than two minutes, corresponding to oral dissolution. 
Others disintegrate over a period of forty to ninety minutes, corresponding to gastric or 
intestinal dissolution.  The disintegration times as determined by using the IsoTMA 
method can aid in designing a drug delivery target. The disintegration rate for capsules 
significantly depends on the temperature and pH of the dissolving fluid.  The percent 
relative error for IsoTMA disintegration rates for both capsules and tablets is about 20%. 
One possible reason for the TMA error might be the difficulty in consistent probe 
placement due to the convex surface of many tablets. Another reason might be the 
embossed logo on the pill causing variations in IsoTMA behavior. We are currently 
assessing these problems with a variety of tablets. We are also evaluating the behavior of 
formulated tablets with longer disintegration times, tablets with minimum curvature and 
imprinted logos and possibly applying higher stress to fix the tablet in place while being 
submersed in the in vitro fluid. Another possible improvement in IsoTMA precision 
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could result from increasing the contact surface area of the quartz probe by using a wider 
diameter rod. 
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CHAPTER  VI 
 
FUTURE STUDIES 
 Instrumentally improve the probe contact area for the fully formulated drugs  
 Evaluate class 1 drugs( anti arithmetic drugs or cardio vascular drugs) 
  Determine disintegration properties by micro Calorimetry and compare with  
              IsoTMA test 
 Implement Iso TMA test for drugs synthesized in medicinal chemistry. 
 Study the effects of a number of known disintegrant on formulated drugs prepared 
in our laboratory. 
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